Posted by Michael Wonder on 24 May 2020
Hikma receives FDA approval for its generic Vascepa
22 May 2020 - Hikma Pharmaceuticals today announces that its wholly owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received approval from the US FDA for its icosapent ethyl 1 g capsules, the generic equivalent to Vascepa.
In March 2020, the United States District Court for the District of Nevada invalidated six key Vascepa patents owned by Amarin. The District Court decision is currently being appealed.
